The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Bioregulators

Chonluten

A Khavinson cytogen peptide aimed at the lungs and bronchial mucosa.

3 min read 8 sources

To the product To the calculator
Vial with white powder, a blue cap and a black TPD label for Chonluten on a white podium, next to it a chain of blue and white glass spheres as a molecule model in a bright lab
No registered trial · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

Length
3 amino acids

Glu-Asp-Gly (EDG), a synthetic tripeptide2

Molar mass
319.3 g/mol

Molecular formula C11H17N3O8, a very small molecule7

Compared in immune cells
5 peptides

Chonluten alongside Epitalon, Vilon, Thymogen and Thymalin in human monocytes2

Human trials in the registry
0 trials

no trial with Chonluten on ClinicalTrials.gov, as of 26 Oct 20268

  • Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG) from the Russian Khavinson programme. There it is regarded as a bioregulator for the lungs and bronchial lining.26
  • In an Italian-Russian cell study it dampened the release of the inflammatory messenger TNF from immune cells stimulated with bacterial components.2
  • Under the code T-34, EDG normalised genes for protective and inflammatory proteins in a model of stomach ulcers.37
  • A review by the Khavinson group mentions use in chronic bronchitis, without figures. There is no registered study on this.4
  • ClinicalTrials.gov lists no trial with Chonluten (as of October 2026). Almost all data come from one research group. Everything here is the state of research, not a recommendation.81
Profile

Updated May 2026

Class
Short bioregulator peptide

Khavinson cytogen

Use
Subcutaneous

in mg

Target tissue
the lungs and bronchial mucosa
Status
Data mostly from the Khavinson program
Sizes
20 mg

1 size in the shop

Contents 15 sections
  1. At a glance
  2. What is Chonluten?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. Side effects
  11. Storage
  12. Related compounds
  13. FAQ
  14. Glossary
  15. Sources

What is Chonluten?

Chonluten is a short peptide from the Russian Khavinson program, which deals with tissue-specific bioregulators. These very short peptides (usually 2 to 4 amino acids) are meant to act specifically on a particular tissue, Chonluten is aimed at the lungs and bronchial mucosa.

Up front: most research comes from a single research line and mostly from Russia, large independent studies are missing.

Comparison

Same family, different building blocks

Short peptides from the Khavinson programme with their amino acid sequence according to a review. Tap a card to open its entry.

Tripeptide, lungs Chonluten EDG
Tetrapeptide, bronchi Bronchogen AEDL Tripeptide, brain Pinealon EDR Tetrapeptide, pineal gland Epitalon AEDG

The assignment to a tissue comes from the Khavinson group itself. It has not been confirmed independently. 6

How it works

The theory behind the Khavinson peptides: they are meant to act at the level of gene regulation and restart age-related declining functions of a tissue. For Chonluten a supportive effect on the lungs and bronchial mucosa is described.

How well this concept transfers to humans is little established outside the originating research.

Where it acts

Where Chonluten acted in experiments

Tap a point or a card. All from cell and animal studies, there is no confirmed receptor.

  1. Lungs

    According to a review by the group used in chronic bronchitis, without figures and without a registered study4

    Observed in trials
  2. Immune cells in the blood

    Human monocytes (cell line): less TNF after stimulation with bacterial components2

    Observed in trials
  3. Stomach

    Stomach ulcer model: genes for protective and inflammatory proteins normalised (as T-34)3

    Observed in trials

Known targets5

Compound PubChem CID 194641: two described targets, all Possible route into the cell, only modelled on the computer (docking).

Peptide transporter PepT1
Gene
SLC15A1
UniProt
P46059
ChEMBL
CHEMBL4605
Action
Possible route into the cell, only modelled on the computer (docking)
Amino acid transporter LAT1
Gene
SLC7A5
UniProt
Q01650
ChEMBL
CHEMBL4459
Action
Possible route into the cell, only modelled on the computer (docking)
Glass lung lobe with round air sacs, small blue molecules and glowing DNA helices inside
Theory: action at the level of gene regulation in the lung and bronchial lining. Symbolic image.

What you need

Supplies

2 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Chonluten vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid

  1. Chonluten vial

    The vial (lyophilized powder, usually 20mg).

    In the shop

  2. Water and supplies

    Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

    In the shop

Reconstitution

Use the peptide calculator. A 20mg vial with 2ml water gives 10mg per ml. Just add the water to the vial and let it dissolve.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 20 mg + 2 ml = 10 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh, or the back of the upper arm.

The short version:

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject slowly, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

What the research shows

The Khavinson program has published numerous works on tissue-specific bioregulators over decades (overview: Khavinson, 2002), including effects on organ function and, in animal models, on lifespan. But the read must stay honest: the data come mostly from one research line, large independent studies are missing.

Top view of petri dishes and pipettes around a clear glass lung model
The data mostly come from one research group, large independent studies are missing. Symbolic image.

Research status

Where the research stands

So far Chonluten has been studied in cell cultures and in an animal model, mostly by the Khavinson group and its partners. As of 26 Oct 2026. 8

  1. Preclinical Cell cultures and a stomach model
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
No registered human trial and no known approval as a medicine. Chonluten has only been studied preclinically so far.8

So far there is no registered trial in humans. 8

Side effects

  • Well tolerated in the available reports, mainly local reactions.
  • Solid, independent human safety data are limited.

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same common ground: all in the TPD lexicon.

Chonluten
Bronchogen Tetrapeptide AEDL, bronchi Cardiogen Tetrapeptide AEDR, heart Cartalax Tripeptide AED, cartilage Epitalon Tetrapeptide AEDG, pineal gland Vilon Dipeptide KE, immune system Vesugen Tripeptide KED, blood vessels Pinealon Tripeptide EDR, brain Thymalin Peptide mixture from the thymus

FAQ

Common questions about Chonluten

Short answers, each backed by the sources below.

Is Chonluten approved or studied in humans?

As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Chonluten. A review by the Khavinson group writes that EDG was given on top of usual care in chronic bronchitis and strengthened its effect. It gives no figures. This has not been checked independently.84

What is Chonluten made of?

Of three amino acids: glutamic acid, aspartic acid and glycine, EDG for short, molecular formula C11H17N3O8. In older papers the same tripeptide is called T-34.27

What did the study in immune cells show?

A group from Italy, together with the Khavinson group, tested five Khavinson peptides on a human monocyte cell line. After stimulation with bacterial components Chonluten dampened the release of TNF. All five peptides lowered TNF and IL-6 in mature macrophages and reduced their sticking to stimulated vessel wall. It was a cell culture without animals and without humans.2

What is known about the stomach?

Under the code T-34 the tripeptide normalised the production of protective and inflammatory proteins in a model of stomach ulcers by influencing the related genes. A review by the group therefore also lists it as protection for the stomach.36

How does Chonluten differ from Bronchogen?

According to the Khavinson group both target the airways. Chonluten is a tripeptide (EDG), Bronchogen a tetrapeptide (AEDL). For Bronchogen there is a rat model of COPD, for Chonluten mainly data from immune cells and the stomach.64

How is such a short peptide supposed to work?

The Khavinson group assumes that short peptides reach the cell nucleus and influence genes. On the computer EDG fits well into the transporters PepT1 and LAT1 of the cell membrane. The group also suspects an effect against tumours through this. Whether this happens in the body has not been shown.5

Which side effects are known?

There are no solid data because Chonluten has never been tested in a registered human trial. Statements about good tolerability come from the research group itself.81

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Bioregulator
Term from the Khavinson programme for short peptides that are meant to target a specific tissue. Not a term used in drug approval.
Bronchial lining
Inner layer of the bronchi with ciliated cells that move mucus and particles upwards and goblet cells that make mucus.
Chronic bronchitis
Long-lasting inflammation of the bronchi with cough and phlegm for months, often after smoking.
Khavinson programme
Research on peptide bioregulators that Vladimir Khavinson has built up in Russia since the 1970s. Most papers come from this group.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
Monocytes
White blood cells that mature into macrophages. In inflammation they release messengers such as TNF.
PepT1 and LAT1
Transporters in the cell membrane for small peptides and amino acids. Whether Chonluten uses them has only been calculated on the computer.
Preclinical
Research before first use in humans, in cell cultures and animal models. Results cannot be transferred directly to humans.
Subcutaneous
Into the fat layer just under the skin.
TNF
Tumour necrosis factor: an important messenger of inflammation. Too much of it damages tissue.
Tripeptide
A chain of exactly three amino acids. For Chonluten these are glutamic acid, aspartic acid and glycine.

Evidence

Sources

Show all 8 sourcesHide sources 5 Studies1 Trial registry2 Database checked 26 Oct 2026

Studies

  1. Five Khavinson peptides in human immune cells

    Avolio et al., International Journal of Molecular Sciences, 2022

    DOI 10.3390/ijms23073607 PMID 35408963
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  2. Peptide T-34 (EDG) in a stomach ulcer model

    Khavinson et al., Bulletin of Experimental Biology and Medicine, 2012

    DOI 10.1007/s10517-012-1590-2 PMID 22803148
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Review by the Khavinson group on peptides in lung diseases

    Khavinson et al., Molecules, 2020

    DOI 10.3390/molecules25194389 PMID 32987757
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  4. Transport of short peptides via PepT1 and LAT1, computer model

    Khavinson et al., Biomolecules, 2023

    DOI 10.3390/biom13030552 PMID 36979488
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  5. Review with names and amino acid sequences of the short peptides

    Khavinson et al., International Journal of Molecular Sciences, 2022

    DOI 10.3390/ijms23147733 PMID 35887081
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)

Trial registry

  1. Search on ClinicalTrials.gov (no trial with the peptide)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Review of peptides and ageing from the Khavinson programme (PubMed record)

    Khavinson, Neuro Endocrinology Letters, 2002 (ohne DOI)

    PMID 12374906
    Checked 26 Oct 2026 via PubMed
  2. Structure of Glu-Asp-Gly in PubChem

    PubChem, U.S. National Library of Medicine (CID 194641)

    Checked 26 Oct 2026 via PubChem

In the shop

Chonluten in the catalog

Sizes, prices and shipping times are on the product page.

To the product